Series: Cardiovascular outcome trials for diabetes drugs
Alogliptin and EXAMINE

MILES FISHER

Abstract
 EXAMINE was an FDA mandated cardiovascular outcome trial with alogliptin. In contrast to other cardiovascular outcome trials with DPP-4 inhibitors, it was performed in subjects with a recent acute coronary syndrome. EXAMINE compared alogliptin and placebo in 5,380 subjects with type 2 diabetes and demonstrated non-inferiority for major cardiovascular events (cardiovascular death, myocardial infarction, stroke) but not superiority. Data on hospitalisation for heart failure were not included in the principal publication. A subsequent publication showed no overall increase in hospitalisation for heart failure with alogliptin, but when subjects with and without baseline heart failure were separated there was a significant increase in the group without heart failure at baseline. No clear clinical benefit has been established for alogliptin, and there are alternatives such as sitagliptin and linagliptin that are not associated with an increase in hospitalisation for heart failure.

Br J Diabetes 2019;19:133-135

Key words: diabetes, cardiovascular outcome trial, alogliptin

Introduction
 Licensing requirements for new anti-diabetes drugs changed in the USA and Europe in 2008 and 2012. The phase III development programme was required to include participants that were more representative of the wider diabetes population, cardiovascular events occurring in the phase III development programme were to be blindly adjudicated to provide information on cardiovascular safety, and a dedicated randomised controlled cardiovascular outcome trial (CVOT) was usually required either before or after licensing. This is the second article in a series which describes and summarises the results of each of these CVOTs in the chronological order in which they were published, describing the primary endpoint and important secondary outcomes from the principal publication, but also directs attention to important subsequent publications of data from subgroups and post hoc analyses.

EXAMINE
 The DPP-4 inhibitor alogliptin was licensed in 2013 by the FDA for use in the USA and by the EMA for use in Europe. A systematic assessment of cardiovascular outcomes in the phase II and phase III trials in the development programme was published in early 2013. Major adverse cardiovascular events (MACE; cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) were adjudicated by an expert endpoint committee blinded to treatment allocation. A total of 13 MACE events were adjudicated in 4,168 patients receiving alogliptin and 10 MACE events were identified in 1,860 patients randomised to comparator therapies, so the incidence rates of MACE were not significantly different between patients treated with alogliptin and comparator therapies. In addition, 10 non-MACE cardiovascular events (angina, arrhythmias, heart failure) occurred with alogliptin and three non-MACE cardiovascular events occurred in patients randomised to the comparator therapies (NS). The number of heart failure events as a single outcome was not described.

A paper describing the design and rationale of EXAMINE was published in 2011. The primary endpoint was detailed as MACE. Hospitalisation for heart failure was not included as a single endpoint, but it was included as a component of a so-called exploratory MACE composite of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, urgent revascularisation for unstable angina, and hospitalisation for heart failure. The principal EXAMINE results were presented in 2013 at the meeting of the European Society of Cardiology (ESC) and published simultaneously in the New England Journal of Medicine (NEJM). The design of the study and key baseline characteristics are described in Box 1. In EXAMINE there was no significant difference in MACE, so non-inferiority was established but not superiority (Figure 1, Box 2). No data on hospitalisation for heart failure were presented at the ESC or published in the NEJM. It is surprising that the editors of the NEJM did not request heart failure results as data on hospitalisation for heart failure were included in the publication of SAVOR-TIMI with saxagliptin in the same edition of the NEJM, and have demonstrated a significant increase in hospitalisation for heart failure in the saxagliptin group.

Data on hospitalisation for heart failure were finally published in the Lancet more than one year later. The analyses presented included the data for hospital admission for heart failure as part of the exploratory MACE composite, and a composite of cardiovascular death and hospitalisation for heart failure. The criteria to
Median age of subjects was 61 years with a median duration of diabetes of 7 years. Mean baseline HbA1c was 8.0% (64 mmol/mol). 100% of subjects had an acute coronary syndrome within 15–90 days before randomisation, 88% myocardial infarction including the index event of acute coronary syndrome, 63% prior percutaneous coronary intervention including the index case and 28% investigator reported heart failure at baseline. 66% of subjects were on metformin, 46% sulfonylureas, 2% thiazolidinediones, 30% insulin.

### Principal result
- No reduction in MACE

### Other results from EXAMINE
- Reported events of hypoglycaemia and serious hypoglycaemia were associated with MACE
- Addition of alogliptin to dual therapy with metformin plus sulfonylurea significantly reduced HbA1c and was well tolerated
- Baseline adiponectin concentration was independently associated with recurrent cardiovascular events and this appeared to be independent of the achieved LDL cholesterol concentration
- The addition of cystatin C or biomarkers of tubular injury did not improve the prediction of eGFR decline beyond common clinical factors and routine laboratory data
- A strong relationship was observed between baseline and 6-month NT-proBNP concentrations and incident major cardiovascular events, particularly hospitalisation for heart failure
- Serial measurement of high-sensitivity troponin I revealed a proportion of patients without clinically recognised events had dynamic or persistently raised values and were at high risk of recurrent events
- In EXAMINE, average clinician-measured blood pressure less than 130/80 mmHg was associated with worsened cardiovascular outcomes

### Discussion
EXAMINE was the second published FDA mandated cardiovascular outcome trial with a new diabetes drug. It showed that alogliptin had no effect on atherosclerotic endpoints. Like the increase in hospitalisation for heart failure that was seen in the SAVOR-TIMI trial with saxagliptin, the possible increase in hospitalisation for heart failure in a subgroup in EXAMINE was unexpected and the mechanisms remain unclear. No increase in hospitalisation for heart failure was seen in the subsequent TECOS trial with sitagliptin, or the CARMELINA and CAROLINA trials with linagliptin. For patients with existing heart failure, or those who are at a high risk of developing heart failure including following an acute coronary syndrome, other alternatives are available, including SGLT2 inhibitors, which significantly reduce heart failure outcomes in people with diabetes.

---

**Box 1** Key features of EXAMINE
- EXAMINE compared alogliptin versus placebo for a median of 18 months in 5,380 subjects
- Median age of subjects was 61 years with a median duration of diabetes of 7 years
- Mean baseline HbA1c was 8.0% (64 mmol/mol)
- 100% of subjects had an acute coronary syndrome within 15–90 days before randomisation, 88% myocardial infarction including the index event of acute coronary syndrome, 63% prior percutaneous coronary intervention including the index case and 28% investigator reported heart failure at baseline
- 66% of subjects were on metformin, 46% sulfonylureas, 2% thiazolidinediones, 30% insulin

**Box 2** Results of the EXAMINE trial
- No reduction in MACE
- Reported events of hypoglycaemia and serious hypoglycaemia were associated with MACE
- Addition of alogliptin to dual therapy with metformin plus sulfonylurea significantly reduced HbA1c and was well tolerated
- Baseline adiponectin concentration was independently associated with increased risk of death from CV causes, all-cause mortality and hospitalisation for heart failure
- Levels of high-sensitivity C-reactive protein were associated with recurrent cardiovascular events and this appeared to be independent of the achieved LDL cholesterol concentration
- The addition of cystatin C or biomarkers of tubular injury did not improve the prediction of eGFR decline beyond common clinical factors and routine laboratory data
- A strong relationship was observed between baseline and 6-month NT-proBNP concentrations and incident major cardiovascular events, particularly hospitalisation for heart failure
- Serial measurement of high-sensitivity troponin I revealed a proportion of patients without clinically recognised events had dynamic or persistently raised values and were at high risk of recurrent events
- In EXAMINE, average clinician-measured blood pressure less than 130/80 mmHg was associated with worsened cardiovascular outcomes

---

**Figure 1.** Eighteen-month estimated event rates (in %) comparing alogliptin and placebo for major adverse cardiovascular events (MACE), total mortality, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke and hospitalisation for heart failure (HFH).
Key messages

- EXAMINE was the second published cardiovascular outcome trial of a diabetes drug, comparing alogliptin and placebo
- In EXAMINE, alogliptin had no effect on atherosclerotic events of cardiovascular death, myocardial infarction or stroke
- An increase in hospitalisation for heart failure was observed in a subgroup who did not have heart failure at baseline, and the mechanism of this increase remains uncertain
- For patients with existing heart failure or who are at high risk of developing failure, SGLT2 inhibitors are a better alternative

Conflict of interest: The author has received payment for advisory boards and/or lectures from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, MSD, NAPP, Novartis, Novo Nordisk, Sanofi, Takeda.

Funding: None.

References